147 related articles for article (PubMed ID: 32149388)
1. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
[TBL] [Abstract][Full Text] [Related]
2. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Krishnaswami S; Chow V; Boy M; Wang C; Chan G
J Clin Pharmacol; 2014 Jan; 54(1):46-52. PubMed ID: 24030917
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
9. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
10. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
12. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
[TBL] [Abstract][Full Text] [Related]
13. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Mohamed MF; Trueman S; Feng T; Anderson J; Marbury TC; Othman AA
J Clin Pharmacol; 2019 Jun; 59(6):856-862. PubMed ID: 30633369
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Gepotidacin in Renal Impairment.
Hossain M; Tiffany C; Raychaudhuri A; Nguyen D; Tai G; Alcorn H; Preston RA; Marbury T; Dumont E
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):560-572. PubMed ID: 32429000
[TBL] [Abstract][Full Text] [Related]
18. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
19. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Shon JH; Kim N; Park SJ; Oh MK; Kim EY; Lee SH; Kim YH; Shin JG
Diabetes Obes Metab; 2014 Oct; 16(10):1028-31. PubMed ID: 24641348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
